73 results about "Diabetes insulin resistance" patented technology

The present disclosure describes methods and apparatus for renal neuromodulation via stereotactic radiotherapy for the treatment of hypertension, heart failure, chronic kidney disease, diabetes, insulin resistance, metabolic disorder or other ailments. Renal neuromodulation may be achieved by locating renal nerves and then utilizing stereotactic radiotherapy to expose the renal nerves to a radiation dose sufficient to reduce neural activity. A neural location element may be provided for locating target renal nerves, and a stereotactic radiotherapy system may be provided for exposing the located renal nerves to a radiation dose sufficient to reduce the neural activity, with reduced or minimized radiation exposure in adjacent tissue. Renal nerves may be located and targeted at the level of the ganglion and / or at postganglionic positions, as well as at pre-ganglionic positions.

The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression and / or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and / or activity of genes involved in Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, and others that can inhibit the function of endogenous RNA molecules, such as endogenous micro-RNA (miRNA) (e.g, miRNA inhibitors) or endogenous short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate PCSK9 gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC), including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules and are useful, for example, in providing compositions to prevent, inhibit, or reduce metabolic diseases traits and conditions, including but not limited to hyperlipidemia, hypercholesterolemia, cardiovascular disease, atherosclerosis, hypertension, diabetis (e.g., type I and / or type II diabetis), insulin resistance, obesity and / or other disease states, conditions, or traits associated with PCSK9 gene expression or activity in a subject or organism.

A compound of the formula wherein R1 is: R5 is: and n, m, Z, R8, R9, R10 and R11 are as defined herein, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly, myocardial ischemia.

The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension.

The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions mediated by excessive glucocorticoid action.

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

The invented healthy edible salt is prepared by mixing with sodium chloride, various amino acid, peptide substance, vitamin B family, polysaccharide, or chitin, antioxidant, nucleic acid seasoning, potassium chloride, calcium salt, magnesium salt, selenium salt, and potassium iodide. It can effectively prevent various diseases, also can prevent osteoporosis, cancer, diabetes, dysinsulinosis, lithiasis, coronary heart disease, senile dementia, bark farus etc. it also possesses the functions of antisenility, antifatigue, antidepression, improving immune power, promoting growth etc.

The invention discloses a traditional Chinese medicine composition for treating insulin dependent diabetes and insulin resistant diabetes. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal raw materials: ginseng, astragalus root, angelica sinensis, stir fried bighead atractylodes rhizome, tuckahoe, Chinese atractylodes, Chinese yam, kudzu root, prepared rehmannia root, fenugreek, white peony root, beef kidney, cinnamon, wolfberry fruit, magnolia vine fruit and the like. The invention also relates to a preparation method of the traditional Chinese medicine composition, and application thereof in preparing medicaments for treating insulin dependent diabetes and insulin resistant diabetes. The composition disclosed by the invention has multiple advantages of good curative effect, convenience in taking, no adverse reaction and the like.

The present invention provides peptide analogues which are antagonists of gastric inhibitory peptide (GIP). The peptides, based on GIP 1-42 include substitutions and / or modifications which have enhanced resistance to degradation by the enzyme dipeptidyl peptidase IV (DPP IV). The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and / or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and / or Syndrome X (metabolic syndrome) and / or loss of pancreatic beta cell function and / or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and / or maintained.

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

There are provided new pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety, and the like or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and / or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.

The present invention provides pharmaceutical compositions comprising antagonists of hepatic sympathetic activity and methods for using said pharmaceutical compositions for treatment of hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridaemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, renal failure, sexual dysfunction, chronic stress, and anxiety.

The invention belongs to the field of pharmacy, relates to novel medicinal application of hydrogen sulfide and a donor thereof sodium hydrosulfide to pharmacy, and in particular relates to application of hydrogen sulfide and donor thereof sodium hydrosulfide to preparation of medicament for treating diabetes. The invention adopts the exogenous hydrogen sulfide and its donor sodium hydrosulfide (NaHS) for insulin sensibilization and tests for regulating blood sugar level and increasing insulin level for type II diabetes. Through correlation test of skeletal muscle and adipose cells with insulin resistance, insulin tolerance test by using animal model for diabetes insulin resistance, glucose consumption experiment, animal model experiment for diabetes insulin resistance and NaHS intervention animal experiment, the results show that NaHS can promote glucose uptake in the presence of insulin, thus indicating insulin enhancement effect. The invention of hydrogen sulfide and the donor thereof sodium hydrosulfide can be used as insulin sensitizers and medicaments for regulating blood sugar level and increasing insulin level for type II diabetes.

The invention provides a substitute five membered heterocyclic compound represented by the following formula, and salt, ester, solvate and metal composition which are all accepted by pharmacy or a prodrug having the same biological activity. The invention also provides a purpose of the compound as a glucagon-like peptide-1 receptor (GLP-1R) signal transduction positive modulator and an application for preventing and / or curing metabolic diseases (including but not being limited to type-2 diabetes, insulin resistance and adiposity, and the like), angiocardiopathy and neurodegenerative diseases (such as Alzheimer's disease, AD) also called presenile dementia, and the like.

The invention provides a compound with substituted cyclobutane structure represented as formula I or II, a relative preparation method, and an application of being glucagon-like peptide-1 receptor modulator to prevent and / or treat metabolic disorder (as diabetes, insulin resistance and obesity or the like), cardiovascular disease and neurodegenerative disease (as Alzheimer's) or the like.

Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.

An method and formulation are provided for the prevention and treatment of adverse ocular conditions which are complications of diabetes. In one embodiment, the invention comprises administering to a person having diabetes, insulin resistance, or a risk factor for diabetes a formulation comprising a metal chelator and a transport enhancer. Most preferably, the metal chelator is EDTA or a salt of EDTA, and the transport enhancer is methylsulfonylmethane (MSM). The formulation may be in a form suitable for application to the eye itself, for example, in the form of eye drops.

The invention provides a compound which is provided with substituted cyclopropane structure represented in the general formula I as follows and a method for preparing the compound and application as hyperglycemic glycogenolytic peptide-1 receptor adjustor for preventing and / or treating metabolic disorder disease (containing but not limited by diabetes, insulin resistance and obesity), cardiovascular disease and nerve degenerative disease (such as Alzheimer's disease) and the like.

The invention provides a compound with a substituted four-membered ring structure represented as formula I or II, relative pharmacy acceptable salt, ester, solvent and metal complex, or prodrug with same pharmacologia function, and ra elative application of being glucagon-like peptide-1 receptor modulator to prevent and / or treat metabolic disorder (as diabetes, insulin resistance and obesity or the like), cardiovascular disease and neurodegenerative disease (as Alzheimer's) or the like.

Provided is a compound having excellent dipeptidyl peptidase IV-inhibiting activity, and a remedy based on the activity for insulin-dependent diabetes (type 1 diabetes), especially for non insulin-dependent diabetes (type 2 diabetes), insulin-resistant disorders, and obesity.

The present invention provides a compound of formula (I): wherein R1-R5, R25, R26, Y, y, and X2 are as defined herein. The compounds activate human peroxisome proliferater activated receptors (hPPARs) and are useful for the treatment of associated disorders such as dyslipidemia, syndrome X, hypercholesteremia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, and obesity.

The present invention provides reagents and methods for identifying inhibitors of the L-type Ca2+ channel β3 protein, which has been demonstrated to be involved in calcium signaling, insulin secretion, and glucose homeostasis. The invention also provides therapeutics and methods for treating a subject with one or more of diabetes, insulin resistance, impaired insulin secretion, and impaired glucose homeostasis, involving the use of inhibitors of an L-type Ca2+ channel β3 subunit to provide a benefit to the subject.

The present invention provides a pharmaceutical composition containing a hypoglycemic agent(s) as an active ingredient for improving or treating impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia. The present invention further provides a pharmaceutical composition for preventing or delaying the progression from impaired glucose tolerance, borderline diabetes, insulin resistance or hyperinsulinemia to diabetes mellitus or metabolic syndromes; or the progression to the state easy to develop macrovascular disorders, cardiovascular events or ischemic heart disease.

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and / or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and / or Syndrome X (metabolic syndrome) and / or loss of pancreatic beta cell function and / or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and / or maintained.